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A B S T R A C T
Cystic Fibrosis (CF) is a genetic disease caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene which encodes for a chloride
ion channel regulating the balance of salt and water across secretory epithelia. Here we generated an iPSC line from a CF patient homozygous for the p.Asn1303Lys
mutation, a Class II folding defect mutation. This iPSC line provides a useful resource for disease modeling and to investigate the pharmacological response to CFTR
modulators in iPSC derived epithelia.
Resource table
Unique stem cell line identifier MHHi018-A
Alternative name(s) of stem cell line CF19_iPSCK9
Institution LEBAO, Hannover Medical School, Germany
Contact information of distributor merkert.sylvia@mh-hannover.de;
martin.ulrich@mh-hannover.de
Type of cell line iPSC
Origin human
Additional origin info Age: 25
Sex: male
Cell Source CD34+ cells from peripheral blood
Clonality clonal
Method of reprogramming Sendai Virus, transgene-free
Genetic Modification no
Type of Modification n/a
Associated disease Cystic Fibrosis, p.Asn1303Lys
Gene/locus CFTR, 7q31.2, c.3909C>G
Method of modification n/a
Name of transgene or resistance n/a
Inducible/constitutive system n/a
Date archived/stock date January 2019
Cell line repository/bank https://hpscreg.eu/cell-line/MHHi018-A
Ethical approval The Local Ethics Committee of Erasmus MC Rotterdam approved the study (internal No.
NL61623.078.17.V03) and informed consent was obtained from the patient.
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1. Resource utility
Our established CFTR_p.Asn1303Lys iPSC line offers a patient-specific
disease model of Cystic Fibrosis and can be used to investigate the
pharmacological response to CFTR modulators in iPSC derived epithelia.
2. Resource details
Cystic Fibrosis (CF) is an autosomal recessive genetic disease caused
by ~350 pathogenic variants in the Cystic Fibrosis Transmembrane
Conductance Regulator (CFTR) gene (https://cftr2.org/ database), en-
coding a cAMP-regulated chloride channel of secretory epithelia, e.g., in
the lungs or the pancreatic ducts (Riordan et al., 1989). p.Asn1303Lys
(N1303K) belongs to the most frequent disease-causing mutations in the
CFTR gene with an allele frequency of 1.58% of all CF chromosomes
varying significantly between countries and ethnic groups (based on
https://cftr2.org/ database_ January 2020). Similar to the more
prominent CFTR p.Phe508del mutation, p.Asn1303Lys is a Class II
mutation, which results in trafficking and gating defects of the chloride
channel (Gregory et al., 1991).
In this study the MHHi018-A iPSC line was generated from a
25-year-old male CF patient carrying a homozygous p.Asn1303Lys
mutation in the CFTR gene. CD34+ hematopoietic stem cells were
isolated from peripheral blood donation and reprogrammed with
CytoTune™-iPS 2.0 Sendai Reprogramming Kit for the generation of
transgene-free iPSCs. Resulting single cell clones were tested in passage
14 after reprogramming by RT-PCR analysis for the absence of Sendai
virus (SeV) and exogenous reprogramming factor transcripts (Suppl.
Fig. A). Clone 9 (MHHi018-A) was chosen for further characterization.
Sanger sequencing confirmed the homozygous presence of the
c.3909C>G mutation in exon 21 of the CFTR gene (Fig. 1A) and a
normal human karyotype 46,XY was detected by fluorescence
R-banding in passage 24 (Fig. 1B). The clone showed typical pluripotent
stem cell like morphology (Fig. 1C) and the expression of the
Fig. 1. Characterization of the MHHi018-A iPSC line.
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pluripotency markers OCT4, NANOG, TRA-1-60 and SSEA-4 could be
confirmed via fluorescence staining and flow cytometry (Fig. 1C and D).
The clone was free from mycoplasma contamination (Suppl. Fig B) and
STR analysis of MHHi018-A has been performed. Due to the lack of
further patient material, the STR analysis of the parental DNA has not
been submitted. Spontaneous embryoid body formation was performed
to verify the differentiation potential of MHHi018-A. Immuno-
fluorescence staining against endodermal (SOX17), ectodermal
(TUBB3) and mesodermal (DESMIN, VE-Cadherin) markers demon-
strated the capacity to differentiate into cells of all three germ layers
(Fig. 1E). Scale bars in all microscopic pictures represent 100 µm. All
results are summarized in Table 1.
3. Materials and methods
3.1. Reprogramming of CD34+ PBHSCs
10 mL peripheral blood was obtained from the CF patient and
peripheral blood mononuclear cells (PBMCs) were collected by Biocoll
density gradient centrifugation. Subsequently, CD34+ cells were iso-
lated using the CD34 MicroBead Kit from Miltenyi Biotec (Cat#130-
046-702) following the manufacturer's instructions.
30.000 CD34+ cells were transduced with the CytoTune™-iPS 2.0
Sendai Reprogramming Kit (Thermo Fisher; KOS MOI = 5, c-Myc
MOI = 5, hKlf4 MOI= 3) for 24 h in StemSpan™ SFEM supplemented
with 100 ng/mL SCF, 50 ng/mL TPO, 100 ng/mL FLT3 and 8 µg/mL
Polybrene. After 4 days the cells were transferred onto mouse em-
bryonic fibroblasts (MEFs) in knockout-DMEM supplemented with 20%
knockout serum replacement, 1 mM L-glutamine, 0.1 mM β-mercap-
toethanol, 1% nonessential amino acid stock (all from Thermo Fisher)
and 10 ng/mL b-FGF (supplied by the Institute for Technical Chemistry,
Leibniz University Hannover, Germany). Cell colonies with appropriate
iPSC morphology were picked on day 14 of reprogramming and ex-
panded clonally (see below). After 12 passages, the temperature shift to
enhance the loss of reprogramming factors was performed for 6 days at
39 °C. Afterwards, iPSCs were split every 5–6 days using Collagenase IV
(Thermo Fisher) in a 1:10 split ratio onto fresh feeder cells and were
maintained at 37 °C under 5% CO2.
3.2. RT-PCR and mutation analysis
Total RNA was isolated from TRIzol®-lysed cells via NucleoSpin®
RNA II Kit (Machery-Nagel) followed by c-DNA synthesis via RevertAid™
H Minus First Strand cDNA Synthesis Kit (Thermo Fisher) using random
primers according to manufacturer's protocol. RT-PCR was performed
with GoTaq® (Promega) polymerase using a Mastercycler ProS
(Eppendorf) with following cycling conditions: initial denaturation at
95 °C for 5 min; 30 cycles of 95 °C for 30 s, 30 s annealing at 55 °C and
72 °C for 30 s; final extension at 72 °C for 5 min.
For mutation analysis, genomic DNA was isolated with QIAamp
blood Mini Kit (Quiagen). 100 ng DNA was amplified with GoTaq®
polymerase using a Mastercycler ProS (Eppendorf). Cycling conditions
were as follows: initial denaturation at 95 °C for 2 min; 35 cycles of
95 °C for 30 s, annealing at 59 °C for 1 min, and 72 °C for 1 min; final
extension at 72 °C for 5 min. The PCR product was purified and sent for
Sanger sequencing to Microsynth Company. Primers are listed in
Table 2.
3.3. Flow cytometry
Before flow cytometry analysis, cells were cultured as single-cell
monolayers in iPS Brew XF (Miltenyi Biotech) on Geltrex®-coated plates
at a seeding density of 3.6 × 104 cells/cm2. For the intracellular
markers OCT4 and NANOG, the cells were detached with Accutase®
(Thermo Fisher) and fixed with 1% PFA for 15 min at room temperature
(RT). The incubation with direct labeled antibodies was performed in
solution B/FIX&PERM® at 4 °C for 20 min. Staining of living cells for the
surface markers SSEA-4 and TRA-1-60 was performed in 1% BSA in PBS
for 20 min at 4 °C. Cells were analyzed with a MACSQuant Analyzer 10
and FlowJo analysis software. Antibodies are listed in Table 2.
3.4. Immunofluorescence staining
Cells were fixed in 4% paraformaldehyde (20 min, RT) and per-
meabilized with triton blocking solution (20 min, RT). Afterwards, cells
were stained with primary antibodies and corresponding isotype con-
trols in 1% BSA in PBS (1 h, RT), followed by washing and incubation
with secondary antibodies (30 min, RT) and DAPI nuclear staining
(15 min, RT). Images were acquired with an AxioObserver A1 fluores-
cence microscope and Axiovision software. Antibodies are listed in
Table 2.
3.5. In vitro differentiation
hiPSCs were detached using a cell scraper and transferred into ultra-
low attachment plates (Corning) in differentiation medium (80% IMDM
supplemented with 20% fetal calf serum, 1 mM L-glutamine, 0.1 mM ß-
mercaptoethanol and 1% nonessential amino acid stock). After 7 days,
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography normal Fig. 1 panel C
Phenotype Qualitative analysis
(Immunocytochemistry)
Positive for OCT4, NANOG, TRA-1-60 Fig. 1 panel C
Quantitative analysis (Flow cytometry) OCT4 (97.2%), NANOG (93.4%), TRA 1-60 (99.8%), SSEA-4 (99.5%) Fig. 1 panel D
Genotype Karyotype (R-banding) and resolution 46XY,
Resolution min 300 bands
Fig. 1 panel B
Identity Microsatellite PCR (mPCR) OR not performed
STR analysis STR profile for 16 specific sites tested available with author
Mutation analysis Sequencing Homozygous for c.3909C>G Fig. 1 panel A
Southern Blot or WGS N/A
Microbiology and virology Mycoplasma Negative Suppl. Fig. panel B
Differentiation potential Embryoid body formation Spontaneous FSC-based in vitro differentiation; positive for ectoderm
(TUBB3), endoderm (SOX17) and mesoderm (DESMIN, VE-Cadherin)
Fig. 1 panel E
Donor screening HIV 1 + 2 Hepatitis B, Hepatitis C Negative not shown but available
with author
Genotype additional info Blood group genotyping N/A
HLA tissue typing N/A
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formed embryoid bodies were plated onto gelatin-coated cell culture
plates in differentiation medium for another 14 days before PFA fixa-
tion and immunofluorescence staining.
3.6. Karyotyping
Adherent cells were incubated at 37 °C with 75 mM potassium
chloride for 20 min and for 30 minutes with colcemide. After trypsi-
nation, metaphases were prepared according to standard procedures.
Fluorescence R-banding using chromomycin A3 and methyl green was
performed and metaphases were captured using a Zeiss Imager.Z2 mi-
croscope and Ikaros software (MetaSystems). At least 14 metaphase
spreads were analysed at a minimum level of 300 bands.
3.7. STR analysis
Cell pellets were provided to Microsynth and profiling was per-
formed using highly-polymorphic short tandem repeat loci (STRs). STR
loci were amplified using the PowerPlex® 16 HS System (Promega).
Fragment analysis was done on an ABI3730xl (Life Technologies) and
the resulting data were analyzed with GeneMarker HID software
(Softgenetics). Tested loci: D3S1358, TH01, D21S11, D18S51, Penta_E,
D5S818, D13S317, D7S820, D16S539, CSF1PO, Penta_D, AMEL, vWA,
D8S1179, TPOX, FGA
3.8. Mycoplasma test
Exclusion of mycoplasma contamination was confirmed by
MycoAlert™ mycoplasma detection kit (Lonza), according to manu-
factures’ instructions. The test exploits the activity of mycoplasmal
enzymes by biochemical luminescence.
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Table 2
Reagents details.
Antibodies used for immunocytochemistry/flow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency Markers mouse anti-OCT4 (IgG2b) 1:100 Santa Cruz Biotechnology Cat# sc-5729, RRID:AB_628051
mouse anti-NANOG (IgG1) 1:500 Abcam Cat# ab62734, RRID:AB_956161
mouse anti-TRA-1-60 (IgM) 1:100 Abcam Cat# ab16288, RRID:AB_778563
RE anti-OCT4_PE 1:25 Miltenyi Biotec Cat# 130-105-554, RRID:AB_2653085
RE anti-NANOG_APC 1:25 Miltenyi Biotec Cat# 130-105-049, RRID:AB_2652991
RE anti-TRA-1-60_PE 1:25 Miltenyi Biotec Cat# 130-100-347, RRID:AB_2654227
RE anti-SSEA4_VioBlue 1:25 Miltenyi Biotec Cat# 130-098-366, RRID:AB_2653521
Differentiation Markers mouse anti-DESMIN (IgG1) 1:20 Progen Cat# 10519, RRID:AB_1541098
goat anti-SOX17 (IgG) 1:200 R&D Systems Cat# AF1924, RRIP:AB_355060
mouse anti-TUBB3 (IgG2a) 1:400 Millipore Cat# 05-559, RRID:AB_309804
rabbit anti-VE-Cadherin (IgG) 1:500 Abcam Cat# ab33168, RRIP:AB_870662
Secondary antibodies Cy™3-AffiniPure donkey anti-mouse IgG 1:200 Jackson ImmunoResearch Labs Cat# 715-165-150, RRID:AB_2340813
Cy™3-AffiniPure donkey anti-goat IgG 1:200 Jackson ImmunoResearch Labs Cat# 705–165-147, RRID:AB_2307351
Cy™3-AffiniPure donkey anti-rabbit IgG 1:200 Jackson ImmunoResearch Labs Cat# 711-165-152, RRID:AB_2307443
Cy™3-AffiniPure Donkey anti-Mouse IgM 1:200 Jackson ImmunoResearch Labs Cat# 715-165-020, RRID:AB_2340811
Primers Target Forward/Reverse primer (5′−3′)
Genotyping CFTR (620 bp) 1981_gggactccaaatattgctgtagt
1982_cttgtcgcgccaggtatttt
Absence of reprogramming factors SeV (181 bp)
RT-PCR
fwd_GGATCACTAGGTGATATCGAGC
rev_ACCAGACAAGAGTTTAAGAGATATGTATC
KOS (528 bp)
RT-PCR
fwd_ATGCACCGCTACGACGTGAGCGC
rev_ACCTTGACAATCCTGATGTGG
Kfl4 (410 bp)
RT-PCR
fwd_TTCCTGCATGCCAGAGGAGCCC
rev_AATGTATCGAAGGTGCTCAA
c-Myc (532 bp)
RT-PCR
fwd_TTACTGACTAGCAGGCTTGTCG
rev_TCCACATACAGTCCTGGATGATG
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